News from the Drug Industry Documents Archive (DIDA)

Tuesday, March 10, 2015

New Seroquel Documents posted to DIDA

110 new documents have been added to the Seroquel collection on the Drug Industry Documents Archive (DIDA).  This collection now contains 351 documents from litigation against UK-based AstraZeneca Pharmaceuticals, the maker of Seroquel, an antipsychotic medication used to treat schizophrenia and bipolar disorder. The plaintiffs alleged the drugmaker failed to warn users of the drug's possibly harmful side effects, including the risk of diabetes and related medical complications.

Tuesday, January 27, 2015

New Celexa Collection posted

The Drug Industry Documents Archive has a new collection:
The Celexa and Lexapro Marketing and Sales Litigation collection contains 115 documents from a class action lawsuit alleging that Forest Pharmaceuticals misled consumers and the medical community about Celexa’s and Lexapro’s efficacy in treating pediatric depression.

*Please note the links now go to the new Industry Documents Digital Library site containing both LTDL and DIDA.

Friday, November 7, 2014

New DIDA site is now in beta!

For the past year we have been developing a new DIDA with expanded functionality and an updated look.  This new DIDA is now accessible alongside a new Legacy Tobacco Documents Library (LTDL) and both are found within the Industry Documents Digital Library portal.  This means all industry archives can now be searched individually or together under one umbrella.

There are two ways to access the DIDA beta site -

2)  From the current DIDA site, there is a link to beta in the top banner as well as a pop up invitation that will appear.

You might want to start by watching the tutorial, also accessible from the Tutorial Videos link at the bottom of each page. 
While we are in beta, we hope as many users as possible will try out the new site, play around with the search functionality and new features, and provide feedback through the survey link located at the top of every page.  We need to know what you like and dislike about the new site in order to make it even better!

Monday, August 18, 2014

Zyprexa Documents and Tamiflu CSRs Added

Zyprexa - The documents in this collection are a portion of those produced in a class action court case that alleged Eli Lilly withheld data on adverse effects such as weight gain and diabetes and participated in off-label marketing of the drug. The documents were first obtained and made public in 2006 by, expert consultant Dr. David Egilman, attorney Jim Gottstein, and journalists Philip Dawdy and Alex Berenson. After a legal battle over public access, the documents were un-sealed and allowed to remain in the public domain. These documents highlight Lilly's marketing strategy of influencing key opinion leaders and its attempts to control the research, the scientific literature and regulatory product labeling to minimize information on adverse effects.

Cochrane study on neuraminidase inhibitors – These are very large, clinical study reports that were used by the authors of “Regulatory information on trials of oseltamivir (Tamiflu) and zanamivir (Relenza) for influenza in adults and children.” A thank you to Peter Doshi at the University of Maryland School of Pharmacy for donating these documents to DIDA. We hope to add another batch of these CSRs releated to Relenza before the year is out.

Please note, we are working hard on major revisions to DIDA to make searching, retrieving and saving documents much easier.  The new release is anticipated at the end of September and we urge you to try out the new site and give us lots of feedback.  

Thursday, March 20, 2014

New Clinical Study Reports Posted

A new collection of documents, Cochrane Review: neuraminidase inhibitors, has been added to the Drug Industry Documents Archive (DIDA).  The documents in this collection are a sampling of  clinical study reports (CSRs) provided by the company Roche to a Cochrane review group conducting a systematic review of neuraminidase inhibitors (anti-influenza drugs) including oseltamivir (Tamiflu). These CSRs are comprehensive, integrated summaries of trials submitted by study sponsors to regulatory bodies in support of marketing applications. The detail in CSRs is evident in their length: approximately 100 times the page length of journal publications of trials.

For more information see the full description under "Investigations" at Cochrane Review: neuraminidase inhibitors 

Thursday, October 3, 2013

Symposium on Institutional Corruption and Big Pharma

The Fall 2013 issue of The Journal of Law, Medicine & Ethics is devoted to a special topic: Institutional Corruption and the Pharmaceutical Industry. 

In this symposium issue, 16 articles investigate the corruption of pharmaceutical policy, each taking a different look at the sources of corruption, how it occurs, and what is corrupted. The authors show that Big Pharma's funding of election campaigns and lobbying skews the legislative process that sets pharmaceutical policy and that certain practices have corrupted medical research, the production of medical knowledge, the practice of medicine, drug safety, the Food and Drug Administration's oversight of the pharmaceutical market, and the trustworthiness of patient advocacy organizations.

Special issue: SYMPOSIUM: Institutional corruption and the pharmaceutical industry.(2013). The Journal of Law, Medicine & Ethics, 41(3). 

Thursday, April 25, 2013

New "Hemophiliac Case" Collection

New collection added today:

Factor VIII or IX Concentrate Blood Products – 58 documents dealing with the marketing and distribution of contaminated AHF (anti-hemophiliac factor) blood products.

A little background: Bayer and its Cutter Laboratories manufactured AHF (anti-hemophiliac factor), a blood product used by hemophiliacs to treat uncontrolled bleeding. In the late 1960s the corporation began manufacturing AHF using pools of blood (plasma) from thousands of donors, often recruited from populations at high risk for hepatitis. In the early 1980s Cutter Laboratories realized that its AHF was contaminated with HIV but its financial investment in the product was considered too high to destroy the inventory. Cutter continued to sell the contaminated AHF to markets willing to accept it, including overseas markets in Asia and Latin America, without the recommended precaution of heat treating the product to eliminate the risk. Customers were not informed of the risk and as a consequence, hemophiliacs who infused the HIV-contaminated AHF tested positive for HIV and developed AIDS.

These documents are from class action litigation against Bayer from both US and Taiwanese plaintiffs. While "the hemo case" involved HIV-infected hemophiliacs in the United States and abroad, these documents focus on the marketing and distribution of contaminated blood products in Asia, the so-called "dumping" aspect of the larger body of cases litigated.
See all "hemo" documents

In addition to the new collection, we have also added documents to our Neurontin Marketing and Sales Practices Litigation collection, a collection of documents on the misrepresentation of Neurontin’s effectiveness.  These 3 new documents are industry conducted research reports of double blind placebo controlled studies to determine the efficacy and safety of Neurontin (gabapentin) for use in migraines.  Please note: These are very lengthy documents (4000+ pages) and may take a while to download.
See the Neurontin Research Reports